Late 2014 NDA for Pfizer's ALO-02 after back pain results
This article was originally published in Scrip
Executive Summary
Pfizer plans to submit a new drug application (NDA) to the US FDA later this year for its tamper-resistant pain drug ALO-02 following positive results from a second Phase III clinical trial, this time in moderate-to-severe chronic low back pain.